Document is current
Any future updates will be listed below
-
Authors
Isozaki, Shotaro
Konishi, Hiroaki
Tanaka, Hiroki
Yamamura, Chikage
Moriichi, Kentaro
Ogawa, Naoki
Fujiya, Mikihiro
-
Funding
Funding for this research was provided by:
Ishidsu Shun Memorial Scholarship
Grants-in-Aid for Scientific Research (19K19477, 19K16484, 25460923, 26460956)
Intractable Disease Health and Labour Sciences Research Grants
- License Information
-
More Information
Article History
Received: 16 December 2021
Accepted: 15 April 2022
First Online: 22 April 2022
Declarations
:
: Approval (R3-113) was obtained from the Institutional Animal Care and Use Committee of Asahikawa Medical University. All animal experiments were performed in compliance with the ARRIVE guidelines. All methods were performed in accordance to relevant guidelines and regulations.
: Not applicable.
: Dr. Fujiya acknowledges grants from Japanese Grants-in-Aid for Scientific Research, grants from Translational Research Network Program of Japan Agency for Medical Research and Development (21K07929), non-financial support from Development and Intractable Disease Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare.Dr. Fujiya reports grants and personal fees from EA Pharma Co., Ltd., AYUMI Pharmaceutical Corporation, AbbVie Inc, Otsuka Pharmaceutical Co., Ltd., ZERIA Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nobelpharma Co., Ltd., Pfizer Inc, Janssen Pharmaceutical K.K., KYORIN Pharmaceutical Co., Ltd., MOCHIDA PHARMACEUTICAL CO.,LTD., Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited, Yakult Honsha Co., Ltd., SHIONOGI & Co., Ltd. and ONO PHARMACEUTICAL CO., LTD., personal fees from AstraZeneca, OLYNPUS Co., Ltd., Sanofi K.K., celltrionhealthcare.jp, Medical Review Co., Ltd., NIHON PHARMACEUTICAL CO., LTD., Horii Pharmaceutical Ind.,Ltd, Alfresa Pharma Corporation, Merck Biopharma Co., Ltd., Mylan Inc., Bayer Yakuhin, Ltd., Boston Scientific Corporation, TEIJIN PHARMA LIMITED and Covidien Japan, Inc., personal fees and non-financial support from FUJIFILM Corporation, and grants from GlaxoSmithKline K.K., Bristol-Myers Company, Eli Lilly Japan K.K., Kanamic Network Co., Ltd., Fuji Chemical Industries Co., Ltd., JIMRO Co., Ltd., Chugai Pharmaceutical Co., Ltd., SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. and Kamui Pharma. Inc.Financial sourceDr. Fujiya reports grants from Japanese Grants-in-Aid for Scientific Research, grants from Translational Research Network Program of Japan Agency for Medical Research and Development (21K07929), non-financial support from Development and Intractable Disease Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare.All the other authors have no competing interests.
